What is it?
Bottom line
5African Mango may be relevant to shoppers comparing botanical weight-management extracts, but it is a poor fit for a nootropic profile unless the page is explicit that cognition evidence is missing and the catalog is mostly extract powders and capsules.
Names, aliases and forms
Mechanisms of action
Seed extract is not a uniform ingredient
4African Mango products can be whole seed powder, seed extract, branded IGOB131-style extract, or capsules filled with extract powder. Label milligrams are not interchangeable unless extract ratio, assay, serving size, and testing are comparable.
Mechanisms do not equal cognitive benefits
8A 2024 animal model explored seed extract chemistry and brain-signaling pathways under a high-fat/high-carbohydrate diet model. That is useful for hypothesis generation, but it does not supply a human nootropic claim.
Potential effects and evidence map
Grade E for nootropic use: human trials and systematic reviews focus on body weight, lipids, glucose, and metabolic markers, while healthy-user focus, memory, mood, and wakefulness outcomes are not established. The only cognition-specific source found for this draft is a 2024 high-fat/high-carbohydrate animal model, which should not be translated into a human nootropic claim.
African Mango should not be presented as a focus or attention nootropic for healthy users.
No reliable human evidence shows that African Mango improves memory or learning.
African Mango should not be positioned as a mental-energy or wakefulness ingredient.
There is no dependable human mood or wellbeing evidence for African Mango as a nootropic.
Typical dosages and timing
The compact dose range reflects the 150 mg twice-daily IGOB131 trial and current 400-500 mg capsule rows. The older 2005 study used 3.15 g/day seed extract for four weeks. None of these doses should be presented as a proven focus or memory dose.
Timing & effect horizon
Available human studies used repeated daily dosing for four to ten weeks for weight-related outcomes. Their duration is not evidence of an acute cognitive effect, a nootropic cycle, or a required off-period.
Safety, side effects and risk profile
There is no reliable human nootropic evidence, and weight-related evidence is limited by small, high-risk-of-bias trials. This is an evidence limitation, not a known health hazard at ordinary doses.
Gas or flatulence was reported in short trials and is a plausible, generally self-limited tolerability issue.
Headache was a reported adverse-event category in a short trial, without evidence here of a frequent or severe general-population hazard.
Difficulty sleeping was a reported adverse-event category in the 10-week trial, with similar incidence in the placebo and active groups.
MSK cites rat data suggesting a possible additive glucose-lowering effect with antidiabetic drugs; clinical relevance in people has not been determined.
One report described dialysis-dependent renal decline after 2.5 months of an African Mango herbal product in a person with pre-existing chronic kidney disease.
No human pregnancy or lactation safety data were located for concentrated African Mango seed extract.
No African Mango-specific U.S. enforcement finding is asserted here. U.S. dietary supplements are not FDA-approved for safety or effectiveness before sale.
Gas, headache, and difficulty sleeping were reported in the 10-week IGOB131 trial, with adverse-event categories similar in the placebo and active groups. These limited data do not establish a stimulant effect or a high general-population risk.
One report described dialysis-dependent renal decline in a person with pre-existing chronic kidney disease after 2.5 months of an African Mango herbal product. It cannot establish causation or a risk rate, but it supports a targeted caution for people with kidney disease rather than a general-population risk claim.
No human pregnancy or lactation safety data were located for concentrated seed extract. This is an evidence gap, not a proven toxicity signal; ordinary food use of the fruit or seed is not equivalent to a concentrated extract.
Interactions and cautions
MSK cites rat data suggesting a possible additive glucose-lowering effect with antidiabetic medicines, but clinical relevance in people has not been determined. The available sources do not establish a verified interaction range or a human dose-adjustment rule.
Legal and regulatory status
United States context (as of 2026): FDA does not approve dietary supplements for safety or effectiveness before they are sold. That regulatory status does not establish that an African Mango extract is effective for weight-related or cognitive outcomes.
Practical buying and quality notes
- Inventory changes over time. Use the live finder to compare stated seed-extract identity, serving amount, and any disclosed standardization; do not infer equivalence across products.
- For powders, price per gram is not enough. Compare extract ratio or standardization, certificate-of-analysis recency, microbial and heavy-metal testing, capsule fill, serving size, and whether the listing is seed extract rather than a generic fruit or food powder.4
FAQ
What dose has been studied?
4A 10-week trial used 150 mg of IGOB131 before lunch and dinner, for 300 mg/day. An earlier four-week study used 3.15 g/day. These are weight-related study doses, not validated doses for focus or memory.
Is there a nootropic cycle or onset?
5Weight-related trials lasted four to ten weeks. Their duration does not establish an acute cognitive onset, a nootropic cycle, or a required off-period.
References
- NCBI Taxonomy. Irvingia gabonensis, Taxonomy ID 79319.
- MSK About Herbs. Irvingia gabonensis.
- Ngondi JL, Oben JE, Minka SR. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids Health Dis. 2005.
- Ngondi JL, Etoundi BC, Nyangono CB, et al. IGOB131 seed extract randomized placebo trial. Lipids Health Dis. 2009.
- Onakpoya I, Davies L, Posadzki P, Ernst E. Irvingia gabonensis for overweight and obesity: systematic review of randomized trials. J Diet Suppl. 2013.
- Lee J, Chung M, Fu Z, et al. Irvingia gabonensis seed extract supplementation: systematic review and meta-analysis. J Am Coll Nutr. 2020.
- Kilincalp S, Basar O, Coban S, Yuksel I. Irvingia gabonensis (African mango): innocent magic formula? Acta Gastroenterol Belg. 2014.
- Hassan YR, El-Shiekh RA, El Hefnawy HM, et al. African mango seed extract in a high-fat/high-carbohydrate animal cognition model. J Ethnopharmacol. 2024.
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements.